TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29605109

Group type: EXPERIMENTAL
Intervention: Video clip
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Telephone conversation with a radiographer
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine appointment letter and information sheet
Number of subjects: 74
Study: 27325327

Group type: EXPERIMENTAL
Intervention: Patient-centered education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic education program
Number of subjects: 0
Study: 24635935

Group type: EXPERIMENTAL
Intervention: rTMS 1000 stimulations/day at 1 Hz and 110% of the motor threshold for 5 consecutive days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rTMS 2000 stimulations/day at 1 Hz and 110% of the motor threshold for 5 consecutive days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rTMS 1000 pulse
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rTMS 2000 pulse
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between 1000 pulse and 2000 pulse treatment arms
Number of subjects: 28
Study: 23754188

Group type: EXPERIMENTAL
Intervention: Rilonacept (2.2 mg/kg or 4.4 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20804367

Group type: EXPERIMENTAL
Intervention: Methyl B12 (64.5 mcg/kg every three days for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methyl B12 responders (30% of subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methyl B12 responders
Number of subjects: 30
Study: 18422809

Group type: EXPERIMENTAL
Intervention: Iron supplementation (Fe-IR)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Iron supplementation (non-iron-replete infants)
Number of subjects: 154
Study: 15882144

Group type: EXPERIMENTAL
Intervention: Ucn 1 infusion (50 microg intravenously over 1 hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12933408

Group type: EXPERIMENTAL
Intervention: Droperidol 5 micro g
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Droperidol 15 micro g
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Droperidol 50 micro g
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control
Number of subjects: 329
Study: 11682935

Group type: EXPERIMENTAL
Intervention: One duck introduced to ponds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Two ducks introduced to ponds
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no ducks introduced)
Number of subjects: 9
Study: 8823899

Group type: EXPERIMENTAL
Intervention: Ganzfeld perceptual field with 1 sec. interstimulus interval
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ganzfeld perceptual field with 2 sec. interstimulus interval
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ganzfeld perceptual field with 3 sec. interstimulus interval
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (clear plastic lenses)
Number of subjects: 143
Study: 1313369

Group type: EXPERIMENTAL
Intervention: Cessation of smoking after myocardial infarction
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Plasma viscosity, white blood cell count, haemoglobin, mean platelet volume
Number of subjects: 1755
Study: 2865093

Group type: EXPERIMENTAL
Intervention: 50 micrograms SMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms SMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 10
Study: 31203109

Group type: EXPERIMENTAL
Intervention: Warm responsiveness to toddler fear
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both warmth and prompt to engage
Number of subjects: 55

Group type: COMPARATOR
Intervention: No-encouragement control
Number of subjects: 55
Study: 30091814

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES), an internet-based psychosocial intervention for substance use disorders.
Number of subjects: 507

Group type: COMPARATOR
Intervention: Therapeutic Education System (TES) and treatment-as-usual (control).
Number of subjects: 507

Group type: COMPARATOR
Intervention: Treatment-as-usual (control).
Number of subjects: 507
Study: 27418551

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF)/vilanterol (VI)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 10000
Study: 27678137

Group type: EXPERIMENTAL
Intervention: Simulation-based training (SBT) before operating room apprenticeship (SIM-OR group)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Simulation-based training (SBT) after operating room apprenticeship (OR-SIM group)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Difference in cumulative score from day 1 to day 4 for SIM-OR group
Number of subjects: 143

Group type: COMPARATOR
Intervention: Difference in cumulative score from day 1 to day 4 for OR-SIM group
Number of subjects: 143
Study: 22795281

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cell culture with pexelizumab
Number of subjects: 356
Study: 20507926

Group type: EXPERIMENTAL
Intervention: Telehealth Education Program (TEP) - ten 1-hr sessions
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 158
Study: 18498916

Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h) ranges >60 mg/L x h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h) ranges <30 mg/L x h(‐1), 30‐60 mg/L x h(‐1), >60 mg/L x h(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12 h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPA AUC(0‐12 h) ranges <30, 30‐60, >60 mg/L x h(‐1)
Number of subjects: 100
Study: 15914981

Group type: EXPERIMENTAL
Intervention: Fluoride-containing slow-release device (SFG)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (non-fluoride slow-release device)
Number of subjects: 174
Study: 12848637

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10561191

Group type: EXPERIMENTAL
Intervention: G-CSF + EPO
Number of subjects: 50

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G-CSF and G-CSF + EPO
Number of subjects: 50
Study: 8777066

Group type: EXPERIMENTAL
Intervention: Maintenance group received calls twice a month for six months
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Maintenance group with > or = 5 lb weight loss and 10% TC decrease
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with > or = 5 lb weight loss and 10% TC decrease
Number of subjects: 115
Study: 1890155

Group type: EXPERIMENTAL
Intervention: 2 mg DHSP
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 mg cyproterone acetate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3882480

Group type: EXPERIMENTAL
Intervention: Squaric acid dibutyl ester (SADBE) treatment on the right side of the scalp
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated control on the left side of the scalp
Number of subjects: 17
Study: 31718637

Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs (10 patients treated with pirfenidone at 2403 mg/day, 1 patient with nintedanib at 300 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs
Number of subjects: 11
Study: 30630794

Group type: EXPERIMENTAL
Intervention: Combined medication of abraxane and trastuzumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single medication of trastuzumab
Number of subjects: 80
Study: 26975590

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (initiated within 24 hours after ICU admission)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Late parenteral nutrition (initiated on the morning of the 8th day in the ICU)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 1440
Study: 23619160

Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ supplementation (2000 IU per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no vitamin D₃ supplementation)
Number of subjects: 24
Study: 19473280

Group type: EXPERIMENTAL
Intervention: Portuguese version of ID-Migraine™
Number of subjects: 142

Group type: COMPARATOR
Intervention: Clinical diagnosis by neurologist (gold standard)
Number of subjects: 142
Study: 16260696

Group type: EXPERIMENTAL
Intervention: High-dose tumor cell vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-dose tumor cell vaccine
Number of subjects: 64
Study: 12473479

Group type: EXPERIMENTAL
Intervention: Antiseptic bonded central venous catheters (Arrowguard Arrow International)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Smooth pure polymer central venous catheters (Infectguard MedexMedical Ltd)
Number of subjects: 181
Study: 9135409

Group type: EXPERIMENTAL
Intervention: Atropine penalisation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Occlusion therapy
Number of subjects: 36
Study: 8034388

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous naloxone
Number of subjects: 17
Study: 3283599

Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11320544

Group type: EXPERIMENTAL
Intervention: Chronic cholecystitis patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 48
Study: 30740698

Group type: EXPERIMENTAL
Intervention: Pono Choices curriculum
Number of subjects: 1783

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1783
Study: 29502374

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day for 9 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Pemetrexed combined with cisplatin chemotherapy (2 cycles followed by 3-week discontinuation)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy group
Number of subjects: 86
Study: 26231973

Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Enhanced TAU (control group)
Number of subjects: 54
Study: 25277614

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 22490487

Group type: EXPERIMENTAL
Intervention: Resistance plus loading dose group (R + L): 200 mg aspirin and 150 mg clopidogrel per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resistance plus routine dose group (R + R): 100 mg aspirin plus 75 mg clopidogrel per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 20018367

Group type: EXPERIMENTAL
Intervention: 0.5 mL of the pandemic vaccine (Fluval P, a monovalent vaccine with 6 microg haemagglutinin per 0.5 mL content and aluminium phosphate gel adjuvant; n=178)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 0.5 mL of the pandemic vaccine and 0.5 mL of the seasonal trivalent vaccine (Fluval AB, a trivalent inactivated whole-virion influenza vaccine; n=177)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 355
Study: 17373172

Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5% imiquimod cream
Number of subjects: 36
Study: 14984731

Group type: EXPERIMENTAL
Intervention: Basic education and support
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Intensive education and support
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1050
Study: 11593109

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 241

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 241
Study: 9533423

Group type: EXPERIMENTAL
Intervention: Combination therapy (captopril up to 100 mg/day + 5 mg bendrofluazide)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 15
Study: 7583988

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with stenosis 70% or greater
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis 50% to 70%
Number of subjects: 3

Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 3
Study: 2655909

Group type: EXPERIMENTAL
Intervention: Dyazide (25 mg hydrochlorothiazide and 50 mg triamterene), one capsule daily for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, one capsule daily for eight weeks
Number of subjects: 0
Study: 29694815

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 202

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 202
Study: 27984412

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring every 3 months
Number of subjects: 1733

Group type: COMPARATOR
Intervention: Control group (office BP measured at 0, 12, and 24 months)
Number of subjects: 1733
Study: 26031551

Group type: EXPERIMENTAL
Intervention: Resistance exercise with whole-body vibration
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resistance exercise without whole-body vibration
Number of subjects: 19
Study: 23206376

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1726
Study: 21751031

Group type: EXPERIMENTAL
Intervention: Posterior fusion with additional osteotomy (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Posterior fusion without additional osteotomy (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) parameters
Number of subjects: 24
Study: 18081732

Group type: EXPERIMENTAL
Intervention: DDP733 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DDP733 0.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DDP733 1.4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16609352

Group type: EXPERIMENTAL
Intervention: Automated method for interpreting bone scans
Number of subjects: 200
Study: 15080819

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.1%) given twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral cyclosporine (3 mg/kg) given once daily
Number of subjects: 30
Study: 11144051

Group type: EXPERIMENTAL
Intervention: Cockroach allergen sensitivity
Number of subjects: 160
Study: 9101691

Group type: EXPERIMENTAL
Intervention: Cash inducement (£5 and £10)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Charity donation (£5 and £10)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no inducement initially, then offered £5 or £10)
Number of subjects: 1000
Study: 8517099

Group type: EXPERIMENTAL
Intervention: Beclomethasone inhaler (50 micrograms)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine 10% spray
Number of subjects: 120
Study: 2875621

Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 0
Study: 28823213

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Triceps skinfold thickness
Number of subjects: 174
Study: 27931575

Group type: EXPERIMENTAL
Intervention: Absorbable biliary stent placement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no stent placement)
Number of subjects: 10
Study: 24885317

Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention by pharmacist 2 or 3 weeks after a new prescription.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care arm (control group).
Number of subjects: 30
Study: 22245725

Group type: EXPERIMENTAL
Intervention: Red labeled cup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blue labeled cup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blue plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: White plate
Number of subjects: 0
Study: 19330394

Group type: EXPERIMENTAL
Intervention: Two-incision THA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mini-posterior THA
Number of subjects: 21
Study: 17952423

Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg) with kolanut (12.5 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Halofantrine (500 mg) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desbutylhalofantrine with kolanut
Number of subjects: 15

Group type: COMPARATOR
Intervention: Desbutylhalofantrine alone
Number of subjects: 15
Study: 16485516

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study: 12439119

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (OAC: omeprazole 20 mg b.d., amoxicillin 1 g b.d., clarithromycin 0.5 g b.d.)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Omeprazole quadruple therapy (OBMT: omeprazole 20 mg b.d., colloidal bismuth subcitrate 120 mg q.i.d., metronidazole 0.5 g t.i.d., tetracycline hydrochloride 0.5 g q.i.d.)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 149
Study: 10203434

Group type: EXPERIMENTAL
Intervention: TAS changed every 48 h
Number of subjects: 166

Group type: COMPARATOR
Intervention: TAS changed every 24 h
Number of subjects: 166
Study: 7595749

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2266673

Group type: EXPERIMENTAL
Intervention: L-lactate (46 mM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate (35 mM + 4 mM acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetate (39 mM)
Number of subjects: 0
Study: 7420419

Group type: EXPERIMENTAL
Intervention: Restricted environmental stimulation therapy (lying on a bed in a dark, silent room) combined with self-management messages
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-management messages
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reduced stimulation environment
Number of subjects: 48
Study: 30503672

Group type: EXPERIMENTAL
Intervention: Current asthma symptoms prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician-diagnosed asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe asthma and asthma with exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent consumption of meat and potatoes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent vigorous exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental tobacco smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current active tobacco smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current wheezing and asthma diagnosis
Number of subjects: 0
Study: 27721089

Group type: EXPERIMENTAL
Intervention: Structured prebriefing
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional prebriefing activities
Number of subjects: 76
Study: 26393386

Group type: EXPERIMENTAL
Intervention: 20 mg/day istradefylline plus sham‐rTMS
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 40 mg/day istradefylline plus sham‐rTMS
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo plus 1 Hz rTMS
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo plus 10 Hz rTMS
Number of subjects: 132
Study: 24193859

Group type: EXPERIMENTAL
Intervention: Home-based infusion therapy (ERT with agalsidase alfa every two weeks)
Number of subjects: 69
Study: 21391018

Group type: EXPERIMENTAL
Intervention: Parent-focused intervention (n = 69)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Child-focused intervention (n = 58)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Non-intervention (control group, n = 56)
Number of subjects: 183
Study: 19263348

Group type: EXPERIMENTAL
Intervention: Patients with vertigo (18 subjects)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control subjects (14 subjects)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison between vertigo and control subjects
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cerebellar asymmetry evaluation
Number of subjects: 32
Study: 17596725

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 0
Study: 15557896

Group type: EXPERIMENTAL
Intervention: Powerlink bifurcated endovascular graft
Number of subjects: 258
Study: 11439413

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 110
Study: 9217961

Group type: EXPERIMENTAL
Intervention: Dubowitz score
Number of subjects: 839
Study: 8481863

Group type: EXPERIMENTAL
Intervention: Learning About AIDS
Number of subjects: 0
Study: 3301457

Group type: EXPERIMENTAL
Intervention: twice daily sustained release theophylline suspension
Number of subjects: 14

Group type: COMPARATOR
Intervention: standard twice daily slow release tablets
Number of subjects: 14
Study: 2502937

Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression CPR (IAC‐CPR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard CPR (S‐CPR)
Number of subjects: 33